» Articles » PMID: 27023611

Differential MiRNA-Expression As an Adjunctive Diagnostic Tool in Neuroendocrine Tumors of the Lung

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2016 Mar 30
PMID 27023611
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Pulmonary malignancies with neuroendocrine differentiation represent a rare subclass of lung carcinomas, which vary in the extent of differentiation and grade of biological aggressiveness. In particular, neuroendocrine tumors are classified into well differentiated typical and atypical carcinoids as well as poorly differentiated large cell neuroendocrine and small cell lung carcinomas. Tiny MicroRNAs have been identified as reliable classifiers in distinct cancer types and seem to play important roles in cellular processes like regulation of cell growth, differentiation and apoptosis. In the present study, two different microRNAs (miR-21 and miR-34a) were explored for their involvements in pathogenesis of subtypes and finally in differential diagnosis of pulmonary neuroendocrine tumors. miR-21 was upregulated in poorly differentiated neuroendocrine tumors (mean rank: 26.8; 28.75) as compared to carcinoids (mean rank: 12.33; 12.07) with a significance of 0.00033. High-expression levels of miR-34a were associated with atypical carcinoids (p = 0.010). A close association is implicated between the elevated miR-21 values in high-grade and miR-34a patterns in low-grade atypical neuroendocrine lung carcinomas, which could potentially be exploited as practical supportive markers for differential lung cancer diagnosis in routine. However, some additional extended research and validation studies are needed to utilize them as routine markers or potential molecular targets for personalized medicine.

Citing Articles

MicroRNAs in lung cancer: their role in tumor progression, biomarkers, diagnostic, prognostic, and therapeutic relevance.

Chatterjee M, Nag S, Gupta S, Mukherjee T, Shankar P, Parashar D Discov Oncol. 2025; 16(1):293.

PMID: 40067551 PMC: 11896959. DOI: 10.1007/s12672-025-02054-9.


Bibliometric and visualized analysis of applying tumor markers in lung cancer diagnosis from 2000 to 2022.

Ke S, Chen S, Jiang Y, Gong H, Yu J, Li X Cancer Innov. 2023; 2(4):265-282.

PMID: 38089746 PMC: 10686150. DOI: 10.1002/cai2.74.


An miRNA Signature Predicts Grading of Pancreatic Neuroendocrine Neoplasms.

Saller J, White D, Hough B, Yoder S, Whiting J, Chen D Cancer Genomics Proteomics. 2023; 20(2):154-164.

PMID: 36870693 PMC: 9989673. DOI: 10.21873/cgp.20370.


MicroRNA in lung cancer-a novel potential way for early diagnosis and therapy.

Frydrychowicz M, Kuszel L, Dworacki G, Budna-Tukan J J Appl Genet. 2023; 64(3):459-477.

PMID: 36821071 PMC: 10457410. DOI: 10.1007/s13353-023-00750-2.


Using biological information to analyze potential miRNA-mRNA regulatory networks in the plasma of patients with non-small cell lung cancer.

Zhang W, Zhang Q, Che L, Xie Z, Cai X, Gong L BMC Cancer. 2022; 22(1):299.

PMID: 35313857 PMC: 8939143. DOI: 10.1186/s12885-022-09281-1.


References
1.
Guthrie J, Seah C, Brown S, Tang P, Jamieson F, Drews S . Use of Bordetella pertussis BP3385 to establish a cutoff value for an IS481-targeted real-time PCR assay. J Clin Microbiol. 2008; 46(11):3798-9. PMC: 2576621. DOI: 10.1128/JCM.01551-08. View

2.
Li T, Li D, Sha J, Sun P, Huang Y . MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun. 2009; 383(3):280-5. DOI: 10.1016/j.bbrc.2009.03.077. View

3.
Mao C, Zhou J, Yang Z, Huang Y, Wu X, Shen H . KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer. PLoS One. 2012; 7(5):e36653. PMC: 3346734. DOI: 10.1371/journal.pone.0036653. View

4.
Bonikos D, Bensch K, JAMPLIS R . Peripheral pulmonary carcinoid tumors. Cancer. 1976; 37(4):1977-98. DOI: 10.1002/1097-0142(197604)37:4<1977::aid-cncr2820370450>3.0.co;2-4. View

5.
Travis W, Travis L, Devesa S . Lung cancer. Cancer. 1995; 75(1 Suppl):191-202. DOI: 10.1002/1097-0142(19950101)75:1+<191::aid-cncr2820751307>3.0.co;2-y. View